Amgen, Kyowa Kirin End Mogamulizumab Pact
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin and Amgen are to cancel an agreement for the Japanese firm’s antibody mogamulizumab, to which Amgen had acquired certain rights under a 2008 deal.